Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 2
2007 2
2009 1
2010 2
2011 5
2012 1
2013 1
2014 1
2015 4
2016 2
2017 5
2018 2
2019 1
2021 1
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas.
Giustiniani J, Ta VA, Belkhelouat S, Battistella M, Ouahbi D, Ram-Wolff C, Louveau B, Mourah S, Bagot M, Moins-Teisserenc H, Ortonne N, Bensussan A, De Masson A. Giustiniani J, et al. J Invest Dermatol. 2024 Mar 28:S0022-202X(24)00259-8. doi: 10.1016/j.jid.2024.03.019. Online ahead of print. J Invest Dermatol. 2024. PMID: 38555062 No abstract available.
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.
Decroos A, Cheminant M, Bruneau J, Carras S, Parinet V, Pelletier L, Lacroix L, Martin N, Giustiniani J, Lhermitte L, Asnafi V, Battistella M, Lemonnier F, De Leval L, Sicard H, Bonnafous C, Gauthier L, Genestier L, Caruso S, Gaulard P, Hermine O, Ortonne N. Decroos A, et al. Among authors: giustiniani j. Haematologica. 2023 Oct 1;108(10):2830-2836. doi: 10.3324/haematol.2022.282220. Haematologica. 2023. PMID: 37165836 Free PMC article. No abstract available.
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.
Gauci ML, Giustiniani J, Lepelletier C, Garbar C, Thonnart N, Dumaz N, Foussat A, Lebbé C, Bensussan A, Marie-Cardine A. Gauci ML, et al. Among authors: giustiniani j. Cancer Immunol Immunother. 2022 Nov;71(11):2731-2742. doi: 10.1007/s00262-022-03199-0. Epub 2022 Apr 15. Cancer Immunol Immunother. 2022. PMID: 35428910 Free PMC article.
CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.
Giustiniani J, Dobos G, Moins-Teisserenc H, Eustaquio T, Battistella M, Ortonne N, Ram-Wolff C, Bouaziz JD, Marie-Cardine A, Mourah S, Bagot M, Kupper TS, Clark RA, Bensussan A, de Masson A. Giustiniani J, et al. Blood Adv. 2022 Jun 14;6(11):3507-3512. doi: 10.1182/bloodadvances.2021006512. Blood Adv. 2022. PMID: 35201316 Free PMC article. No abstract available.
Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit.
Hocine HR, Brunel S, Chen Q, Giustiniani J, San Roman MJ, Ferrat YJ, Palacios I, de la Rosa O, Lombardo E, Bensussan A, Charron D, Jabrane-Ferrat N, Al-Daccak R. Hocine HR, et al. Among authors: giustiniani j. Stem Cells Transl Med. 2019 Sep;8(9):911-924. doi: 10.1002/sctm.18-0256. Epub 2019 Mar 28. Stem Cells Transl Med. 2019. PMID: 30924311 Free PMC article.
Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.
Menguy T, Briaux A, Jeunesse E, Giustiniani J, Calcei A, Guyon T, Mizrahi J, Haegel H, Duong V, Soler V, Brousset P, Bensussan A, Raymond Letron I, Le Bouteiller P. Menguy T, et al. Among authors: giustiniani j. Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2687-2698. doi: 10.1167/iovs.18-24024. Invest Ophthalmol Vis Sci. 2018. PMID: 29860455
CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases.
Henry A, Boulagnon-Rombi C, Menguy T, Giustiniani J, Garbar C, Mascaux C, Labrousse M, Milas C, Barbe C, Bensussan A, Durlach V, Arndt C. Henry A, et al. Among authors: giustiniani j. Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2679-2686. doi: 10.1167/iovs.18-24021. Invest Ophthalmol Vis Sci. 2018. PMID: 29860454
36 results